Phase III Prostate Cancer Failures: Taxotere to Blame?
Executive Summary
Had a Phase III failure? Don't believe the data. Trial design, concurrent therapies, patient selection, or even the conventional diagnostic indicator for the disease could be at fault, as illustrated by a handful of late-stage trip-ups during 2007.
You may also be interested in...
Algeta Recruits Bayer To Deliver Prostate Cancer Drug Alpharadin To Market
Big Pharma still hot for castration-resistant prostate cancer drugs, despite Phase III burns in the past.
Call the Plumber: PIPE Logic is Leaky
Extraordinary times for capital markets have made cheap public biotechs attractive to venture investors. These private investments in public equity (PIPEs) are seen by some as a lifeline to a troubled and undervalued sector, and many VCs are considering significant public investments. But few deals are likely to get done as venture funds set a high bar for investment, regardless of fire-sale prices. Recipients of large PIPE deals may indeed provide venture-like returns for private investors, but an analysis of these financings shows why they are the exceptions that prove the rule.
Call the Plumber: PIPE Logic is Leaky
Extraordinary times for capital markets have made cheap public biotechs attractive to venture investors. These private investments in public equity (PIPEs) are seen by some as a lifeline to a troubled and undervalued sector, and many VCs are considering significant public investments. But few deals are likely to get done as venture funds set a high bar for investment, regardless of fire-sale prices. Recipients of large PIPE deals may indeed provide venture-like returns for private investors, but an analysis of these financings shows why they are the exceptions that prove the rule.